In advanced EGFR mutant NSCLC, tumors with concurrent TP53 or RB1 mutations then further disrupted genome stability and exerted higher risks for histological transformation and TKI resistance15. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.